Clinical Trials Directory

Trials / Completed

CompletedNCT02448225

18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules

PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
46 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

This clinical trial compares fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET)/computed tomography (CT) to the standard of care fluorodeoxyglucose F-18 (18F-FDG) PET/CT in imaging patients with newly diagnosed lung cancer or indeterminate pulmonary nodules. PET/CT uses a radioactive glutamate (one of the common building blocks of protein) called 18F-FSPG which may be able to recognize differences between tumor and healthy tissue. Since tumor cells are growing, they need to make protein, and other building blocks, for cell growth that are made from glutamate and other molecules. PET/CT using a radioactive glutamate may be a more effective method of diagnosing lung cancer than the standard PET/CT using a radioactive glucose (sugar), such as 18F-FDG.

Detailed description

PRIMARY OBJECTIVES: I. To compare the imaging characteristics of 18F-FSPG PET/CT with standard-of-care, 18F-FDG PET/CT. II. To compare the imaging characteristics of 18F-FSPG PET/CT to standard-of-care 18F-FDG PET/CT in patients with newly diagnosed lung cancer. III. To determine whether 18F-FSPG uptake in lung cancer can be predicted based on correlation with CD44 and amino acid transport system xc- (xC-) expression in surgical pathology specimens. OUTLINE: Patients undergo 18F-FDG PET/CT scan per standard of care. Within 15 working days, patients also undergo 18F-FSPG PET scan over 60 minutes followed by an 18F-FSPG PET/CT scan over 30 minutes. After completion of study, patients are followed up for 2 years if needed for diagnosis.

Conditions

Interventions

TypeNameDescription
PROCEDUREComputed TomographyUndergo 18F-FDG PET/CT - standard of care
PROCEDUREComputed TomographyUndergo 18F-FSPG PET/CT
RADIATIONfluorodeoxyglucose F-18Undergo 18F-FDG PET/CT - standard of care
DRUGFluorine F 18 L-glutamate Derivative BAY94-9392Undergo 18F-FSPG PET/CT
OTHERLaboratory Biomarker AnalysisCorrelative studies
PROCEDUREPositron Emission TomographyUndergo 18F-FDG PET/CT - standard of care
PROCEDUREPositron Emission Tomography (PET)Undergo 18F-FSPG PET/CT

Timeline

Start date
2015-06-16
Primary completion
2021-08-02
Completion
2022-10-10
First posted
2015-05-19
Last updated
2022-10-19
Results posted
2022-05-10

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02448225. Inclusion in this directory is not an endorsement.